Eleos Health vs Upheal
An enterprise evidence platform against a solo first AI native EHR, and the buyer decides it. Eleos brings the deepest published evidence of any documentation adjacent vendor here, a randomised trial and a 2.83 million micro dialogue accuracy study, the broadest coverage including substance use disorder and field care, and a checkable 80 percent acceptance rate, but it gates pricing and publishes no security attestation or data stewardship position. Upheal is the more legible product for a smaller practice: an all in one AI native EHR with the most buyer favourable pricing in the category, a completed SOC 2 Type II, and a published BAA, though its evidence is thin and it fits multi site organisations poorly. If you are an enterprise behavioral health organisation needing published evidence and broad coverage, start with Eleos. If you are a solo or virtual first practice wanting a transparent all in one with clear compliance, start with Upheal.
- The deepest published evidence base of any documentation adjacent vendor in the index, graded A: a randomised clinical trial in the Journal of Medical Internet Research plus a real world accuracy study across more than 2.83 million micro dialogues, where Upheal has no peer reviewed study located and grades C.
- The broadest coverage in the category, graded A on setting: behavioral health, substance use disorder treatment, and home health across office, telehealth, and field settings, serving clinicians, supervisors, and compliance teams, where Upheal fits solo, small group, and virtual first practices and is a poor fit for larger multi site organisations.
- A checkable autonomy claim, graded A: an approximate 80 percent suggestion acceptance rate, where Upheal publishes no edit burden figure and has reported speaker identification issues in independent user feedback.
- The most buyer favourable pricing in the category, graded A: $1 per session capped at $69 per month with everything included and no add on, where Eleos gates pricing and grades C, so cost scales with caseload.
- A completed security attestation and a readable contract, both graded A: SOC 2 Type II and a published Business Associate Agreement plus PHIPA, where Eleos has no located attestation and is unrated on PHI stewardship.
- An all in one AI native EHR with a built in telehealth room and Golden Thread linkage maintaining documented continuity between diagnosis, plan goals, and progress notes for medical necessity, serving both the keep your EHR and replace it paths, graded A on interoperability.
Side-by-Side
| Axis | E Eleos Health |
U Upheal |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both grade A on AI centrality and interoperability, but they aim at different buyers, which frames the choice. Eleos is the enterprise platform whose edge is published evidence, including a randomised trial rare in this index, though small at 47 participants and single site, and the broadest setting coverage. Upheal is the solo and virtual first AI native EHR whose edge is legibility: the most buyer favourable pricing in the category, a completed SOC 2 Type II, and a published BAA, all of which Eleos lacks. The same inversion seen across this category applies, the cheaper tool carrying the clearer attestations while the enterprise platform carries the stronger clinical evidence. Both grade C on clinical evidence only for Upheal; Eleos is the exception at A. Both grade C on governance, and Upheal's session analytics add a sentiment layer supervisors may act on.